Sotera Health (SHC)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$18.90-0.68%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · SHC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 28.8% |
| Our one-year growth estimate | diamond | 6.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 22.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 32 industry peers · Company calendar date is not available
SHC — director transition
Dated 2026-08-14
Director — James C. Neary: A Class I director resigned effective shortly after notification with no stated disagreement, representing a standard board turnover event rather than an executive crisis.
Why it matters: Sterigenics is an important part of the business. Its success shows how well the company is doing and its growth chances.
Supportive ifSterigenics reports revenue growth above 6.1% year over year.
Worry ifSterigenics reports revenue growth below 6.1% year over year.
Why it matters: Changes in leadership can affect plans and how well they grow.
Watch forThere are good updates on the new CEO's effect on plans.
Also watch forThere are bad comments or worries about the leadership change.
Why it matters: Sotera Health's revenue growth is crucial for its outlook. A slowdown could signal deeper issues in the business or market.
Worry ifQ2 revenue growth falls below 5.0% year over year.
Less concerning ifQ2 revenue growth exceeds 6.5% year over year.
Why it matters: Updates on capital use show how the company will handle debt and investments. This matters for financial stability.
Watch forManagement shares new investment plans or debt cuts after the credit deal.
Also watch forNo news or plans to raise debt without a good reason.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$108 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $268 loss on $10,000 · 2.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,214 loss on $10,000 · 32.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on capital allocation show how the company will handle its debt and investments. This impacts financial health.
Watch forManagement shares a plan to cut debt or boost cash flow.
Also watch forNo news or a negative view on how money will be spent.
Why it matters: A higher net leverage ratio may mean more financial risk. This can affect the company's ability to invest.
Worry ifNet leverage ratio reported above 3.5x in the next earnings report.
Less concerning ifNet leverage ratio reported at or below 3.2x.
Why it matters: Higher capex could indicate aggressive growth plans or potential cash flow issues.
Worry ifCapital spending was above $225 million for 2026.
Less concerning ifCapital spending was between $200 million and $225 million.
Why it matters: This would signal a slowdown in growth, raising concerns about demand and execution.
Worry ifQ3 2026 net revenues growth reported below 5.25% year over year.
Less concerning ifQ3 2026 net revenues growth meets or exceeds 5.25% year over year.
Why it matters: The new CEO may change strategies that affect growth and operations. Investors will monitor if the transition leads to improved performance.
Watch forPositive revenue growth in the quarters following the CEO transition.
Also watch forRevenue or earnings may drop after the CEO change.
Why it matters: The new CEO's plan could change the company's future. It may also affect investor trust.
Watch forA detailed strategic plan is announced by the new CEO within the next quarter.
Also watch forNo strategic plan is announced or the plan lacks clear growth initiatives.
Why it matters: How the company spends money can affect growth and profits. Investors will watch for any changes.
Watch forManagement shares a new plan that focuses on growth investments.
Also watch forManagement sticks with the current plan without making any changes.
Why it matters: Sotera's performance is tied to the health care sector's growth phase; any slowdown could impact results.
Worry ifSector revenue growth drops below its median, indicating a slowdown.
Less concerning ifIf sector revenue growth stays stable or gets better, it helps Sotera's performance.
Why it matters: A drop in margin shows rising costs or problems. This affects how much money is made.
Worry ifIn Q3 2026, Adjusted EBITDA margin was below 51.6%.
Less concerning ifIn Q3 2026, Adjusted EBITDA margin was at or above 51.6%.
Why it matters: The new CEO's vision will affect future growth. Changes in leadership can impact investor trust and company direction.
Supportive ifThe new CEO outlines a clear growth strategy during a public event or call.
Worry ifThe new CEO does not share a clear strategy or faces big challenges.
Why it matters: A smooth change could make things more stable. It may boost investor trust in the company.
Supportive ifThe new CEO leads the company well. There are no major issues in the first few months.
Worry ifThe change causes big problems or bad news.